| Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767) |
|---|
| 07/05/2001 | WO2001047915A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | WO2001047914A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | WO2001047905A1 Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | WO2001047904A1 Thiazolyl amide derivatives |
| 07/05/2001 | WO2001047901A1 Ox(adi)azolyl-hydroxamic acids useful as procollagen c-proteinase inhibitors |
| 07/05/2001 | WO2001047897A1 Cytokine, especially tnf-alpha, inhibitors |
| 07/05/2001 | WO2001047896A1 Benzimidazoles, production thereof and the use thereof as antithrombotic |
| 07/05/2001 | WO2001047892A1 Tricyclic protein kinase inhibitors |
| 07/05/2001 | WO2001047887A1 β-AMINO ACID COMPOUNDS AS INTEGRIN ANTAGONISTS |
| 07/05/2001 | WO2001047886A1 Nitrile derivatives as cathepsin k inhibitors |
| 07/05/2001 | WO2001047885A1 Substituted indole mannich bases |
| 07/05/2001 | WO2001047880A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | WO2001047879A1 Pyrrolidines which inhibit camp-specific pde |
| 07/05/2001 | WO2001047878A1 Substituted pyrrole mannich bases to combat pain and allergic reactions |
| 07/05/2001 | WO2001047866A1 Substituted 1 and 2 naphthol mannich bases |
| 07/05/2001 | WO2001047859A1 Compounds active at the glucocorticoid receptor |
| 07/05/2001 | WO2001047533A2 INHIBITION OF GSK-3$g(b) |
| 07/05/2001 | WO2001047530A1 A method of therapy and prophylaxis of inflammation |
| 07/05/2001 | WO2001047493A1 Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate |
| 07/05/2001 | WO2001003720A9 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 07/05/2001 | WO2001000824A3 HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS |
| 07/05/2001 | WO2000073278A3 5-phenyl-pyrimidine derivatives |
| 07/05/2001 | WO2000070046A3 Secreted polypeptides and corresponding polynucleotides |
| 07/05/2001 | WO2000068195A3 Substituted pyrrolidines as cell adhesion inhibitors |
| 07/05/2001 | US20010007020 Antibodies that bind to the nidogen-binding domain of laminin, their production and use |
| 07/05/2001 | US20010006973 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels |
| 07/05/2001 | US20010006962 Behavior of biologically active compounds favorably modified by replacing a functional group with an unsaturated fatty derivative, e.g. elaidic acid; bioavailability; membrane passage; organ targeting; drugs; agriculture |
| 07/05/2001 | US20010006957 Microdispersed or microfibrillar polyanhydroglucuronic acids and salts, complex salts or intermolecular polymer complexes suitable for fixing drug dosages with significantly protracted effect and reduced toxicity |
| 07/05/2001 | US20010006944 Treating noninvasive fungus-induced rhinosinusitis by mucoadministering an antifungal agent; culturing noninvasive fungus from a mammalian mucus sample for antigen/antibody production; apparatus for collecting nasal mucus |
| 07/05/2001 | US20010006939 Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions |
| 07/05/2001 | US20010006799 Histidine kinase polypeptides |
| 07/05/2001 | US20010006656 Comprising an aerosol formulation of a 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor, said HMG-CoA reductase inhibitor being present at a concentration of less than 0.1 mg |
| 07/05/2001 | DE19963178A1 Substituierte Indol-Mannichbasen Substituted indole Mannich bases |
| 07/05/2001 | CA2699568A1 Azaindoles |
| 07/05/2001 | CA2397710A1 Streptococcus pyogenes virulence genes and proteins and their use |
| 07/05/2001 | CA2396693A1 Cytokine, especially tnf-alpha, inhibitors |
| 07/05/2001 | CA2396579A1 Tricyclic protein kinase inhibitors |
| 07/05/2001 | CA2396502A1 Substituted pyrrole mannich bases |
| 07/05/2001 | CA2395663A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | CA2395544A1 Method of achieving persistent transgene expression |
| 07/05/2001 | CA2395543A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | CA2395284A1 Inhibition of gsk-3.beta. |
| 07/05/2001 | CA2395236A1 Basolateral sorting signal and inhibitors thereof |
| 07/05/2001 | CA2395179A1 Nitrile derivatives as cathepsin k inhibitors |
| 07/05/2001 | CA2395173A1 Pyrrolidines which inhibit camp-specific pde |
| 07/05/2001 | CA2394727A1 Pyrimidine and triazine kinase inhibitors |
| 07/05/2001 | CA2394098A1 Substituted 1 and 2 naphthol mannich bases |
| 07/05/2001 | CA2393916A1 Benzimidazoles, the preparation thereof and their use as pharmaceutical compositions |
| 07/05/2001 | CA2393583A1 Compounds active at the glucocorticoid receptor |
| 07/05/2001 | CA2393529A1 Inhibitors of complement activation, their preparation and use |
| 07/05/2001 | CA2392866A1 Substituted indole mannich bases |
| 07/04/2001 | EP1112738A2 Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine |
| 07/04/2001 | EP1112381A1 Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases |
| 07/04/2001 | EP1112266A1 Substituted 4-amino-2-aryl-pyrimidines, their production and use and pharmaceutical preparations containing same |
| 07/04/2001 | EP1112262A1 SUBSTITUTED $g(g)-PHENYL-$g(D)-LACTONES AND ANALOGS THEREOF AND USES RELATED THERETO |
| 07/04/2001 | EP1112255A1 4,4-biarylpiperidine derivatives with opioid receptor activity |
| 07/04/2001 | EP1112251A1 Azetidine derivatives, preparation and medicines containing them |
| 07/04/2001 | EP1112083A2 Use of an angiogenic factor for the treatment of microvascular angiopathies |
| 07/04/2001 | EP1112082A2 Stable liquid formulations of botulinum toxin |
| 07/04/2001 | EP1112070A1 Novel substituted triazole compounds |
| 07/04/2001 | EP0850236B1 Piperazino derivatives as neurokinin antagonists |
| 07/04/2001 | EP0579615B1 New bi- and tricyclic aminoalcohol esters, their preparation and their use in medicaments |
| 07/04/2001 | CN1302376A Corticotropin releasing factor receptor-1 deficient mice |
| 07/04/2001 | CN1302296A Novel 2-alkyl substituted imidazole compounds |
| 07/04/2001 | CN1302183A Xylitol compositions for treating upper respiratory conditions |
| 07/04/2001 | CN1301566A Method for producing Chinese medicine for curing dyspneic cough |
| 07/04/2001 | CN1301565A Method for producing nasopharynx pill |
| 07/04/2001 | CN1301551A Compound Rhododendron seniavinii granule |
| 07/04/2001 | CN1301550A Compound rhododendron senivainii granule and its preparing method |
| 07/04/2001 | CN1301534A Stable slow-releasing oral administration composition |
| 07/04/2001 | CN1067986C 1H-indole-3-acetic acid hydrazide phospholipid enzyme A2 inhibitors |
| 07/03/2001 | US6255512 High energy oxidizing agents in explosive compositions, propellant formulations, gas-generating compositions, andpharmaceutical agents |
| 07/03/2001 | US6255468 MPROT12 polynucleotides and methods thereof |
| 07/03/2001 | US6255453 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors |
| 07/03/2001 | US6255303 Bronchodilator agent |
| 07/03/2001 | US6255281 Complexing uteroglobin to fibronectin |
| 07/03/2001 | US6254882 Ion exchanging of drug delivery |
| 07/03/2001 | US6254875 Methods for use of OMP26 from Haemophilus influenzae |
| 07/03/2001 | US6254853 Drugs with carriers |
| 07/03/2001 | US6253762 Metered dose inhaler for fluticasone propionate |
| 07/03/2001 | CA2132512C Bioadhesive pharmaceutical composition used for the controlled release of active ingredient |
| 07/03/2001 | CA2116348C Sirs vaccine and diagnosis method |
| 06/30/2001 | CA2293852A1 Procedure for preparing active plant extracts used to trap free radicals; the extracts and compounds and devices containing them |
| 06/28/2001 | WO2001046443A2 Proteases |
| 06/28/2001 | WO2001046392A2 Homologues of human heparanase and splice variants thereof |
| 06/28/2001 | WO2001046263A1 Novel compounds |
| 06/28/2001 | WO2001046261A1 Method for treating inflammation |
| 06/28/2001 | WO2001046258A2 Transporters and ion channels |
| 06/28/2001 | WO2001046256A2 Vesicle trafficking proteins |
| 06/28/2001 | WO2001046255A1 Nk cell receptor polynucleotides, polypeptides, and antibodies |
| 06/28/2001 | WO2001046200A1 Novel piperidine and piperazine derivatives |
| 06/28/2001 | WO2001046196A1 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
| 06/28/2001 | WO2001046191A1 4-[aryl(8-azabicyclo[3.2.1]octan-3-yl)]aminobenzoic acid derivatives |
| 06/28/2001 | WO2001046184A1 3-thiazol-4-yl-pyprolidine derivatives as amp-specific phosphodiesterase inhibitors |
| 06/28/2001 | WO2001046183A1 SUBSTITUTED 1,3,4-OXADIAZOLES AND A METHOD OF REDUCING TNF-α LEVELS |
| 06/28/2001 | WO2001046176A2 Non peptide tachykinin receptor antagonists |
| 06/28/2001 | WO2001046174A1 Novel compounds |
| 06/28/2001 | WO2001046172A1 Pyrazole cyclic amp-specific pde inhibitors |
| 06/28/2001 | WO2001046168A1 Tryptase inhibitors |
| 06/28/2001 | WO2001046167A1 α-ARYLETHYLPIPERAZINE DERIVATIVES AS NEUROKININ ANTAGONISTS |